Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

In vitro data supporting interferon plus cytotoxic agent combinations.

D D Von Hoff1

  • 1Cancer Therapy and Research Center of South Texas, San Antonio.

Seminars in Oncology
|October 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

Cancer chemotherapy and pharmacology·2014
Same author

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.

European journal of cancer (Oxford, England : 1990)·2012
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

This study found that combining interferon alfa (rIFN-alpha) with certain chemotherapy drugs like doxorubicin, fluorouracil, and etoposide shows synergistic antitumor effects in vitro. These promising combinations warrant further clinical trials for cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Research

Background:

  • The human tumor cloning system is a validated in vitro assay.
  • This assay predicts patient response to antineoplastic and biologic agents.
  • It also screens novel cytotoxic and biologic agents for antitumor activity.

Purpose of the Study:

  • To investigate synergistic combinations of interferon alfa (rIFN-alpha) and cytotoxic agents.
  • To evaluate these combinations using the human tumor cloning system in vitro.

Main Methods:

  • Utilized the human tumor cloning system for in vitro drug sensitivity testing.
  • Assessed combinations of rIFN-alpha with doxorubicin, fluorouracil, and etoposide.
  • Evaluated synergism across diverse tumor types.

Related Experiment Videos

Main Results:

  • Significant synergism was observed for doxorubicin + rIFN-alpha.
  • Synergistic effects were also noted for fluorouracil + rIFN-alpha.
  • Etoposide + rIFN-alpha demonstrated significant synergism across various tumor types.

Conclusions:

  • Selected combinations of interferon alfa and cytotoxic agents exhibit in vitro synergism.
  • These findings support the clinical investigation of these combined therapies.
  • The human tumor cloning assay is valuable for identifying effective combination cancer treatments.